NASDAQ · COLL
Healthcare · Drug Manufacturers - Specialty & Generic
$23.36
Down-$0.44 (-1.88%)
Updated Sep 10, 2026, 11:02 PM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
COLL closed at $23.36 after 20 trading sessions, down 9.11% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $23.56 | $24.11 | $23.115 | $23.36 | 1.08M |
| Sep 8, 2026 | $23.33 | $23.82 | $23.11 | $23.37 | 1.11M |
| Sep 4, 2026 | $23.54 | $24.32 | $23.37 | $23.53 | 901.14K |
| Sep 3, 2026 | $24.30 | $24.425 | $23.64 | $23.70 | 859.17K |
| Sep 2, 2026 | $24.15 | $24.815 | $23.84 | $24.30 | 852.66K |
| Sep 1, 2026 | $24.85 | $25.46 | $23.93 | $24.00 | 1.41M |
| Aug 31, 2026 | $25.12 | $25.425 | $24.465 | $24.61 | 1.04M |
| Aug 28, 2026 | $26.32 | $26.6865 | $25.16 | $25.35 | 813.95K |
| Aug 27, 2026 | $27.26 | $27.41 | $26.21 | $26.44 | 850.15K |
| Aug 26, 2026 | $27.58 | $28.25 | $27.01 | $27.51 | 613.19K |
| Aug 25, 2026 | $27.47 | $27.755 | $27.13 | $27.47 | 551.9K |
| Aug 24, 2026 | $27.08 | $27.985 | $26.87 | $27.35 | 758.45K |
| Aug 21, 2026 | $27.68 | $27.68 | $26.96 | $27.11 | 704.93K |
| Aug 20, 2026 | $28.35 | $28.50 | $27.25 | $27.54 | 606.61K |
| Aug 19, 2026 | $28.89 | $29.65 | $28.51 | $28.74 | 769.36K |
| Aug 18, 2026 | $28.40 | $28.76 | $28.10 | $28.50 | 800.21K |
| Aug 17, 2026 | $28.37 | $29.01 | $27.87 | $28.07 | 865.11K |
| Aug 14, 2026 | $27.59 | $28.52 | $27.135 | $28.23 | 695.33K |
| Aug 13, 2026 | $27.77 | $29.30 | $27.22 | $28.15 | 1.56M |
| Aug 12, 2026 | $26.50 | $26.50 | $25.47 | $25.70 | 1.12M |
The latest Smart Investors Daily articles mentioning COLL.
COLL research
Company profile and research snapshot.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Leerink Partners | Outperform | — |
| Sep 9, 2026 | Truist Securities | Buy | — |
| Aug 19, 2026 | Barclays | Overweight | — |
| Aug 7, 2026 | Piper Sandler | Neutral | — |
| Aug 6, 2026 | Needham | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 19, 2026
Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $56 to $48.
Benzinga · Aug 7, 2026
Piper Sandler analyst David Amsellem reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $45 to $43.
SeekingAlpha · Aug 7, 2026
2026-08-07. The following slide deck was published by Collegium Pharmaceutical, Inc.
SeekingAlpha · Aug 6, 2026
Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call August 6, 2026 8:00 AM EDTCompany ParticipantsIan Karp - Head of Investor RelationsVikram...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning COLL.
